Not applicableApproved For MarketingNCT06132191
What this trial is testing
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Basal Cell Carcinoma (BCC)Cutaneous Squamous Cell Carcinoma (CSCC)
Regeneron Pharmaceuticals